Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Adolescent
Antineoplastic Agents, Alkylating
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Child
Child, Preschool
Cisplatin
/ administration & dosage
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Etoposide
/ administration & dosage
Female
Humans
Induction Chemotherapy
/ methods
Infant
Male
Neuroblastoma
/ drug therapy
Prognosis
Prospective Studies
Thailand
Topoisomerase I Inhibitors
/ administration & dosage
Topotecan
/ administration & dosage
Treatment Outcome
Vincristine
/ administration & dosage
High risked neuroblastoma
Induction therapy
Prognostic factor
Topotecan
Treatment response
Treatment-related toxicity
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
16 Oct 2019
16 Oct 2019
Historique:
received:
05
06
2019
accepted:
23
09
2019
entrez:
18
10
2019
pubmed:
18
10
2019
medline:
27
2
2020
Statut:
epublish
Résumé
Neuroblastoma is the most common extra-cranial solid tumor among children. Despite intensive treatment, patients with advanced disease mostly experience dismal outcomes. Here, we proposed the use of topotecan and cyclophosphamide containing induction regimen as an upfront therapy to high risk neuroblastoma patients. Patients with high risk neuroblastoma undergoing ThaiPOG high risk neuroblastoma protocol from 2016 to 2017 were studied. All patients received 6 cycles of induction regimen consisting of 2 cycles topotecan (1.2 mg/m In all, 107 high risk neuroblastoma patients were enrolled in the study. After the 5th cycle of induction regimen, the patients achieved complete response (N = 2), very good partial response (N = 40), partial response (N = 46) and mixed response (N = 19). None of the patients experienced stable disease or disease progression. The most significant prognostic factor was type of healthcare system. The most common adverse effect was febrile neutropenia followed by mucositis, diarrhea and elevated renal function. The topotecan and cyclophosphamide containing induction regimen effectively provides favorable treatment response. The regimen is well tolerated with minimal toxicity among patients with high risk neuroblastoma in Thailand.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroblastoma is the most common extra-cranial solid tumor among children. Despite intensive treatment, patients with advanced disease mostly experience dismal outcomes. Here, we proposed the use of topotecan and cyclophosphamide containing induction regimen as an upfront therapy to high risk neuroblastoma patients.
METHODS
METHODS
Patients with high risk neuroblastoma undergoing ThaiPOG high risk neuroblastoma protocol from 2016 to 2017 were studied. All patients received 6 cycles of induction regimen consisting of 2 cycles topotecan (1.2 mg/m
RESULTS
RESULTS
In all, 107 high risk neuroblastoma patients were enrolled in the study. After the 5th cycle of induction regimen, the patients achieved complete response (N = 2), very good partial response (N = 40), partial response (N = 46) and mixed response (N = 19). None of the patients experienced stable disease or disease progression. The most significant prognostic factor was type of healthcare system. The most common adverse effect was febrile neutropenia followed by mucositis, diarrhea and elevated renal function.
CONCLUSION
CONCLUSIONS
The topotecan and cyclophosphamide containing induction regimen effectively provides favorable treatment response. The regimen is well tolerated with minimal toxicity among patients with high risk neuroblastoma in Thailand.
Identifiants
pubmed: 31619207
doi: 10.1186/s12885-019-6186-z
pii: 10.1186/s12885-019-6186-z
pmc: PMC6796460
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Topoisomerase I Inhibitors
0
Vincristine
5J49Q6B70F
Etoposide
6PLQ3CP4P3
Topotecan
7M7YKX2N15
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
961Références
J Clin Oncol. 2017 Aug 1;35(22):2580-2587
pubmed: 28471719
J Clin Oncol. 2011 Nov 20;29(33):4351-7
pubmed: 22010014
Children (Basel). 2018 Aug 28;5(9):null
pubmed: 30154341
J Natl Cancer Inst. 2014 Sep 01;106(8):dju166
pubmed: 25178694
J Clin Oncol. 2009 Jan 10;27(2):289-97
pubmed: 19047291
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):312-320
pubmed: 28209594
Indian J Pediatr. 2017 Jun;84(6):446-455
pubmed: 28367616
Nan Fang Yi Ke Da Xue Xue Bao. 2013 Aug;33(8):1107-10
pubmed: 23996746
J Natl Cancer Inst Monogr. 2013;2013(46):7-12
pubmed: 23962507
Expert Rev Anticancer Ther. 2017 Apr;17(4):369-386
pubmed: 28142287
Oncologist. 2004;9 Suppl 6:4-13
pubmed: 15616145
Pediatr Blood Cancer. 2013 Oct;60(10):1636-41
pubmed: 23650219
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Indian J Pediatr. 2012 Jun;79(6):787-92
pubmed: 22528697
Oncologist. 2004;9 Suppl 6:43-52
pubmed: 15616149
Arch Pediatr. 2004 Jul;11(7):834-42
pubmed: 15234382
Oncologist. 2004;9 Suppl 6:33-42
pubmed: 15616148
Annu Rev Med. 2015;66:49-63
pubmed: 25386934
Children (Basel). 2018 Oct 31;5(11):null
pubmed: 30384486
J Clin Oncol. 2001 Aug 1;19(15):3463-9
pubmed: 11481351
J Clin Oncol. 2009 Mar 1;27(7):1007-13
pubmed: 19171716
Eur J Cancer. 2011 Mar;47(4):572-8
pubmed: 21112775
Semin Radiat Oncol. 2008 Jul;18(3):161-7
pubmed: 18513625
Cancer. 2015 Nov 1;121(21):3885-93
pubmed: 26218755
J Clin Oncol. 2010 Aug 20;28(24):3808-15
pubmed: 20660830
Lancet Oncol. 2017 Apr;18(4):500-514
pubmed: 28259608
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
J Clin Oncol. 1998 Mar;16(3):945-52
pubmed: 9508177
Pediatr Clin North Am. 2008 Feb;55(1):97-120, x
pubmed: 18242317
J Clin Oncol. 1993 Aug;11(8):1466-77
pubmed: 8336186
J Pharm Pract. 2012 Apr;25(2):209-221
pubmed: 22307093
Cancer. 2017 Jul 1;123(13):2516-2523
pubmed: 28241089
Int J Health Serv. 2011;41(2):209-30
pubmed: 21563621
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Curr Opin Pediatr. 2019 Feb;31(1):14-20
pubmed: 30480556
J Pediatr Hematol Oncol. 2007 Feb;29(2):101-6
pubmed: 17279006